来凯医药与礼来在美国就LAE102针对肥胖症治疗临床合作 - 老虎社区

资讯资讯
帖子帖子
精选精选

- 月牙泉月牙泉
  ·2024-11-20
  说说你对这篇新闻的看法...
  港股收盘 | 来凯医药飙升48%，与礼来合作；信达生物涨超8%，小鹏汽车跌超3%
  2024年11月20日，港股市场收盘涨跌不一。来凯医药升逾48%，消息面上，公司午间公告，集团已与礼来签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临牀开发。礼来将负责在美国执行一项I期研究并承担相关费用。小米将今年电动车交付目标提升至13万辆，物联网业务毛利率首次超过20%。小鹏汽车绩后跌约4.5%，花旗料小鹏四季度将面临下行压力。$信达生物$上涨8.08%。
  港股收盘 | 来凯医药飙升48%，与礼来合作；信达生物涨超8%，小鹏汽车跌超3%
  3,672 评论
  点赞
  分享
  举报

{"themeInfo":{"themeId":"07e0b9a8029060879506d5b591f8f763","name":"来凯医药与礼来在美国就LAE102针对肥胖症治疗临床合作","description":"来凯医药与礼来签订了一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益，并致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。","image":"https://static.tigerbbs.com/1201dcc0482be040348fb8d4f228bb68","type":2,"style":4,"follow":false,"createTime":1732077915637,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":07e0b9a8029060879506d5b591f8f763}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowSubscriptionFinancial":false,"subscriberCount":0,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["159938","LLY","02105.HK","02105"],"tweetCounts":1,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"来凯医药与礼来在美国就LAE102针对肥胖症治疗临床合作","tweetAmount":1,"imageIsDefault":false,"aiDerivativeIssues":[]},"tab":"news","newsList":[{"id":91110,"article_id":"2484487197","title":"加快减肥药研发 来凯医药与礼来展开临床合作","subtitle":"","subtitle_show":0,"pub_time":1732104339000,"source_id":"stock_eastmoney","language":"zh","url":"http://finance.eastmoney.com/a/202411203245710159.html","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"02105":1,"LLY":1},"rights":null},{"id":91003,"article_id":"1197360722","title":"港股收盘 | 来凯医药飙升48%，与礼来合作；信达生物涨超8%，小鹏汽车跌超3%","subtitle":"","subtitle_show":0,"pub_time":1732090266143,"source_id":"","language":"zh","url":"","is_publish_highlight":1,"top_time":0,"symbols_score_info":{"HSCEI":1,"HSI":1,"HSTECH":1},"rights":null},{"id":90999,"article_id":"1121112381","title":"异动解读 | 来凯医药-B与礼来合作加快肥胖症药LAE102研发，概念股盘中大涨43%","subtitle":"","subtitle_show":0,"pub_time":1732089687931,"source_id":"ai_movement_cn","language":"zh","url":"","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"02105":1},"rights":null},{"id":90977,"article_id":"2484715622","title":"来凯医药：与礼来合作开发肥胖症药物LAE102","subtitle":"","subtitle_show":0,"pub_time":1732082515000,"source_id":"stock_eastmoney","language":"zh","url":"http://finance.eastmoney.com/a/202411203245449466.html","is_publish_highlight":0,"top_time":0,"symbols_score_info":{},"rights":null},{"id":90985,"article_id":"2484599781","title":"来凯医药(02105.HK)曾飙升近四成 与礼来就治疗肥胖药签订临床合作协议","subtitle":"","subtitle_show":0,"pub_time":1732082100000,"source_id":"aastocks_highlight","language":"zh","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1398155/latest-news/AAFN","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"02105":1},"rights":null},{"id":90991,"article_id":"2484153140","title":"来凯医药与礼来合作在美国开展LAE102治疗肥胖症的临床试验","subtitle":"","subtitle_show":0,"pub_time":1732080858000,"source_id":"","language":"zh","url":"1948079","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"02105":1,"LLY":1},"rights":null},{"id":90975,"article_id":"2484166153","title":"来凯医药与礼来签署LAE102临床合作协议","subtitle":"","subtitle_show":0,"pub_time":1732080459000,"source_id":"stock_eastmoney","language":"zh","url":"http://finance.eastmoney.com/a/202411203245418615.html","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"02105":1,"LLY":1},"rights":null},{"id":90987,"article_id":"2484154559","title":"来凯医药与礼来在美国就LAE102针对肥胖治疗达成合作","subtitle":"","subtitle_show":0,"pub_time":1732077022000,"source_id":"tencent","language":"zh","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120145038abd1364f&s=b","is_publish_highlight":0,"top_time":0,"symbols_score_info":{},"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120145038abd1364f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true}},{"id":90965,"article_id":"2484302137","title":"来凯医药-B(02105)与礼来签订一项临床合作协议","subtitle":"","subtitle_show":0,"pub_time":1732076241000,"source_id":"stock_zhitongcaijing","language":"zh","url":"http://www.zhitongcaijing.com/content/detail/1213300.html","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"LLY":1},"rights":null}],"isFinancial":true,"allList":[{"id":373065640075336,"gmtCreate":1732090681933,"gmtModify":1732090683475,"author":{"id":"3520974512346195","authorId":"3520974512346195","name":"月牙泉","avatar":"https://static.tigerbbs.com/926b856b6e4d501dc5a52e4f752a09a2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3520974512346195","authorIdStr":"3520974512346195"},"themes":[],"title":"","htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373065640075336","repostId":"1197360722","repostType":2,"repost":{"id":"1197360722","kind":"news","weMediaInfo":{"introduction":"行情速递","home_visible":1,"media_name":"行情速递","id":"1091154019","head_image":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f"},"pubTimestamp":1732090266,"share":"https://www.laohu8.com/m/news/1197360722?lang=zh_CN&edition=full","pubTime":"2024-11-20 16:11","market":"hk","language":"zh","title":"港股收盘 | 来凯医药飙升48%，与礼来合作；信达生物涨超8%，小鹏汽车跌超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197360722","media":"行情速递","summary":"2024年11月20日，港股市场收盘涨跌不一。来凯医药升逾48%，消息面上，公司午间公告，集团已与礼来签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临牀开发。礼来将负责在美国执行一项I期研究并承担相关费用。小米将今年电动车交付目标提升至13万辆，物联网业务毛利率首次超过20%。小鹏汽车绩后跌约4.5%，花旗料小鹏四季度将面临下行压力。$信达生物$上涨8.08%。","content":"<html><head></head><body><p>2024年11月20日，港股市场收盘涨跌不一。恒生指数上涨0.21%，国企指数上涨0.12%，恒生科技指数上涨0.41%，红筹指数上涨0.39%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/8a9c09e999dbf235e3b88fb5138aa129\" tg-width=\"765\" tg-height=\"154\"/></p><p><br/>板块方面，港股SaaS概念股表现活跃，港股区块链概念股、港股烟草股、港股药品股、港股抗疫概念股、港股生物技术、港股纸业概念股、港股电影股、港股苹果概念股、港股影视娱乐股、恒大系、港股航空股、港股铝业股、港股医美股、港股医药外包概念股、港股医药股、港股汽车股、港股物业管理等板块涨跌不一。</p><p>来凯医药升逾48%，消息面上，公司午间公告，集团已与礼来签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临牀开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。集团致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。</p><p><a href=\"https://laohu8.com/S/01810\">小米集团-W</a>下跌1.06%。摩根大通将小米目标价从24港元上调至34港元，报告指出小米在第三季度实现强劲盈利，核心收入同比增长17%，电动车业务亏损有所收窄。小米将今年电动车交付目标提升至13万辆，物联网业务毛利率首次超过20%。摩根大通认为小米的核心盈利将保持强劲，物联网和智能手机业务毛利率有上升潜力，电动车业务也在稳步发展，预计明年将推出新车型。<br/><br/><a href=\"https://laohu8.com/S/06030\">中信证券</a>上涨1.34%。港股AI应用概念股全线爆发，汇量科技、医渡科技、第四范式等股票涨幅较大。分析机构认为，科技产业的投资主线将继续围绕AI展开。<br/><br/><a href=\"https://laohu8.com/S/09633\">农夫山泉</a>下跌1.87%。农夫山泉创始人钟睒睒在多篇新闻中谈论拼多多的价格体系对中国产业的伤害，强调政府应该干预。他认为这种价格导向是一种产业导向，对中国品牌和产业造成巨大伤害。<br/><br/><a href=\"https://laohu8.com/S/09868\">小鹏汽车-W</a>下跌3.08%。小鹏汽车发布“史上最强财报”，2024年第三季度毛利率创新高，达15.3%；营业收入环比增长24.5%，达101亿元。小鹏汽车董事长兼首席执行官何小鹏认为，这体现了公司变革后的体系能力全面提高，并且正在进入大产品周期。小鹏汽车绩后跌约4.5%，花旗料小鹏四季度将面临下行压力。<br/><br/><a href=\"https://laohu8.com/S/01801\">信达生物</a>上涨8.08%。全球首个用于长期体重管理的胰高糖素样肽-1受体激动剂周制剂诺和盈在上海复旦大学附属中山医院开出全国首批处方，减重版司美格鲁肽正式在国内商业化上市。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股收盘 | 来凯医药飙升48%，与礼来合作；信达生物涨超8%，小鹏汽车跌超3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股收盘 | 来凯医药飙升48%，与礼来合作；信达生物涨超8%，小鹏汽车跌超3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1091154019\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">行情速递 </p>\n<p class=\"h-time\">2024-11-20 16:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>2024年11月20日，港股市场收盘涨跌不一。恒生指数上涨0.21%，国企指数上涨0.12%，恒生科技指数上涨0.41%，红筹指数上涨0.39%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/8a9c09e999dbf235e3b88fb5138aa129\" tg-width=\"765\" tg-height=\"154\"/></p><p><br/>板块方面，港股SaaS概念股表现活跃，港股区块链概念股、港股烟草股、港股药品股、港股抗疫概念股、港股生物技术、港股纸业概念股、港股电影股、港股苹果概念股、港股影视娱乐股、恒大系、港股航空股、港股铝业股、港股医美股、港股医药外包概念股、港股医药股、港股汽车股、港股物业管理等板块涨跌不一。</p><p>来凯医药升逾48%，消息面上，公司午间公告，集团已与礼来签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临牀开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。集团致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。</p><p><a href=\"https://laohu8.com/S/01810\">小米集团-W</a>下跌1.06%。摩根大通将小米目标价从24港元上调至34港元，报告指出小米在第三季度实现强劲盈利，核心收入同比增长17%，电动车业务亏损有所收窄。小米将今年电动车交付目标提升至13万辆，物联网业务毛利率首次超过20%。摩根大通认为小米的核心盈利将保持强劲，物联网和智能手机业务毛利率有上升潜力，电动车业务也在稳步发展，预计明年将推出新车型。<br/><br/><a href=\"https://laohu8.com/S/06030\">中信证券</a>上涨1.34%。港股AI应用概念股全线爆发，汇量科技、医渡科技、第四范式等股票涨幅较大。分析机构认为，科技产业的投资主线将继续围绕AI展开。<br/><br/><a href=\"https://laohu8.com/S/09633\">农夫山泉</a>下跌1.87%。农夫山泉创始人钟睒睒在多篇新闻中谈论拼多多的价格体系对中国产业的伤害，强调政府应该干预。他认为这种价格导向是一种产业导向，对中国品牌和产业造成巨大伤害。<br/><br/><a href=\"https://laohu8.com/S/09868\">小鹏汽车-W</a>下跌3.08%。小鹏汽车发布“史上最强财报”，2024年第三季度毛利率创新高，达15.3%；营业收入环比增长24.5%，达101亿元。小鹏汽车董事长兼首席执行官何小鹏认为，这体现了公司变革后的体系能力全面提高，并且正在进入大产品周期。小鹏汽车绩后跌约4.5%，花旗料小鹏四季度将面临下行压力。<br/><br/><a href=\"https://laohu8.com/S/01801\">信达生物</a>上涨8.08%。全球首个用于长期体重管理的胰高糖素样肽-1受体激动剂周制剂诺和盈在上海复旦大学附属中山医院开出全国首批处方，减重版司美格鲁肽正式在国内商业化上市。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/09caddfc0c2d2ea28b3db992baa72dbf","relate_stocks":{"HSI":"恒生指数","HSTECH":"恒生科技指数","HSCEI":"国企指数"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197360722","content_text":"2024年11月20日，港股市场收盘涨跌不一。恒生指数上涨0.21%，国企指数上涨0.12%，恒生科技指数上涨0.41%，红筹指数上涨0.39%。板块方面，港股SaaS概念股表现活跃，港股区块链概念股、港股烟草股、港股药品股、港股抗疫概念股、港股生物技术、港股纸业概念股、港股电影股、港股苹果概念股、港股影视娱乐股、恒大系、港股航空股、港股铝业股、港股医美股、港股医药外包概念股、港股医药股、港股汽车股、港股物业管理等板块涨跌不一。来凯医药升逾48%，消息面上，公司午间公告，集团已与礼来签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临牀开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。集团致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。小米集团-W下跌1.06%。摩根大通将小米目标价从24港元上调至34港元，报告指出小米在第三季度实现强劲盈利，核心收入同比增长17%，电动车业务亏损有所收窄。小米将今年电动车交付目标提升至13万辆，物联网业务毛利率首次超过20%。摩根大通认为小米的核心盈利将保持强劲，物联网和智能手机业务毛利率有上升潜力，电动车业务也在稳步发展，预计明年将推出新车型。中信证券上涨1.34%。港股AI应用概念股全线爆发，汇量科技、医渡科技、第四范式等股票涨幅较大。分析机构认为，科技产业的投资主线将继续围绕AI展开。农夫山泉下跌1.87%。农夫山泉创始人钟睒睒在多篇新闻中谈论拼多多的价格体系对中国产业的伤害，强调政府应该干预。他认为这种价格导向是一种产业导向，对中国品牌和产业造成巨大伤害。小鹏汽车-W下跌3.08%。小鹏汽车发布“史上最强财报”，2024年第三季度毛利率创新高，达15.3%；营业收入环比增长24.5%，达101亿元。小鹏汽车董事长兼首席执行官何小鹏认为，这体现了公司变革后的体系能力全面提高，并且正在进入大产品周期。小鹏汽车绩后跌约4.5%，花旗料小鹏四季度将面临下行压力。信达生物上涨8.08%。全球首个用于长期体重管理的胰高糖素样肽-1受体激动剂周制剂诺和盈在上海复旦大学附属中山医院开出全国首批处方，减重版司美格鲁肽正式在国内商业化上市。","news_type":1,"symbols_score_info":{"HSI":1,"HSCEI":1,"HSTECH":1}},"isVote":1,"tweetType":1,"viewCount":3672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"essenList":[],"allBottom":false,"essenBottom":true}